News

This newly identified lead compound is from a program being evaluated as a potential treatment for inflammatory pain and is the sixth lead compound identified through the collaboration.

The randomized, double-blind, placebo-controlled, international Phase III trial is designed to evaluate the therapeutic benefit of Rebif (interferon beta-1a) on the time to conversion to multiple sclerosis (MS)

Earlier preclinical data showed that enzyme replacement therapy with Enobia’s product ENB-0040, significantly increases survival and prevents bone hypomineralization associated with hypophosphatasia, a rare genetic bone disease. In

Study results show that approximately half of patients who received ipilimumab (10mg/kg) remained alive beyond one year. The results are based on follow-up of the patient population from

In the 12-week placebo-controlled study, known as the Sirocco trial, neither the active comparator donepezil nor AZD3480 met the trial’s criteria for statistical significance on the primary outcome

Results from a Phase II, randomized, non-comparative study showed that 54% of patients with stage III/IV treatment-naive NSCLC receiving the combination CP-751,871 plus carboplatin and paclitaxel (n=97) experienced

The interim data demonstrated that treatment with the proprietary recombinant full-length human parathyroid hormone (PTH 1-84) had a beneficial effect on abnormal bone skeletal properties in patients with

Calando’s first siRNA therapeutic, CALAA-01, which targets the M2 subunit of ribonucleotide reductase, is currently in a Phase I clinical trial. Calando intends to move CALAA-02 into the

In his new position, Mr Barr will be responsible for the continued features and capabilities expansion of Prism, Nextrials’s clinical trial management software and electronic data capture solution.